Eight years after pivotal data were presented publicly supporting its use in first-line advanced ovarian cancer after surgery, Roche's VEGF inhibitor Avastin finally has been approved by the US FDA for this indication.
The June 13 approval covers treatment with Avastin (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin as a single agent, for women with Stage III or IV...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?